Most vaccines for diseases in low- and middle-income countries fail to be developed because of weak or absent market incentives. Conquering diseases such as tuberculosis, HIV, malaria, and Ebola, as well as illnesses caused by multidrug-resistant pathogens, requires considerable investment and a new sustainable model of vaccine development involving close collaborations between public and private sectors. In this perspective article, co-authors Rino Rappuoli, Steven Black, and David E. Bloom study past successes to glean applicable lessons for the future of vaccine R&D for LMICs.
For more info, contact:
Harvard T.H. Chan School of Public Health